Psychedelics and Inflammation: What Cannabis Readers Should Know

Psychedelics are usually discussed in terms of perception, mood, and mental health. However, researchers are investigating another possibility: some of these substances may also influence the immune system. If that effect translates into meaningful benefits for patients, it could broaden our understanding of how psychedelic therapies work.

A systematic review and meta-analysis by Anna Skovgaard Lerche and colleagues, published online in Brain, Behavior, and Immunity on September 28, 2026, examines that possibility.¹ The findings suggest anti-inflammatory effects in laboratory and animal experiments, particularly when inflammation is already elevated. Human evidence remains too limited and inconsistent to establish the same benefit.

For cannabis readers, the relevance is the scientific question rather than a shared drug category. While cannabis was not evaluated directly in this review, both fields illustrate the challenge of turning promising biological effects into reliable medical treatments.

What the Psychedelic Inflammation Review Found

The researchers screened 9,195 records and included 61 studies: 24 involving cells, 30 involving non-human animals, and seven human studies containing data from 10 separate trials. Their search covered research available through February 9, 2026.

The review focused on serotonergic psychedelics, whose characteristic psychedelic effects involve the serotonin 2A receptor, commonly abbreviated as 5-HT2A. These include substances such as psilocybin, LSD, and DMT, alongside experimental compounds. The findings should not be extended automatically to ketamine or MDMA, which fall outside this definition.

Most cell and animal studies reported anti-inflammatory effects. The researchers also pooled results from 18 eligible mouse and rat studies, finding a significant reduction in pro-inflammatory cytokines in inflammatory models. Cytokines are chemical messengers that help coordinate immune responses.

These counts describe how often studies reported an effect. They do not show the percentage of patients who would benefit, and they do not make every experiment equally persuasive.

Why Baseline Inflammation Could Matter

The contrast between inflammatory models and healthy animals is particularly important. The pooled reduction in pro-inflammatory cytokines was substantial in inflammatory models, with a standardized mean difference of -1.23. Healthy animals showed no statistically significant change.

That number expresses a difference relative to variability within the studies. It does not mean inflammation fell by 123%, nor does it predict a particular reduction in pain or disease severity.

The pattern raises a useful hypothesis: an intervention might have greater effects when inflammatory pathways are already activated. Testing a substance only in healthy volunteers could therefore miss an effect that appears in people with a particular inflammatory condition.

Patient Selection May Shape Future Results

This suggests a possible direction for clinical research. Trials could measure inflammation before treatment and investigate whether participants with elevated markers respond differently. However, the review found only one human study that included participants with confirmed elevated baseline inflammation alongside a comparison group.

There is consequently no validated blood test from this research that identifies who should receive psychedelic treatment. The value of the finding is that it improves the next research question: which patients, with which biological features, might benefit from which compound?

Why Lower Inflammatory Markers Do Not Prove Treatment Benefits

Inflammation is a necessary part of immune defense and tissue repair. The medical objective is not simply to drive every inflammatory marker downward. It is to address harmful immune activity while preserving useful functions.

Likewise, a lower cytokine measurement does not automatically establish improvement in arthritis, inflammatory bowel disease, or depression. A treatment must demonstrate outcomes that matter to patients, such as better functioning, reduced disease activity, or sustained symptom improvement.

Timing also complicates interpretation. Across the reviewed literature, measurements were taken from one hour to six months after exposure. An immediate response and a change several months later may reflect different processes.

For example, longer-term changes could potentially involve altered stress, sleep, or behavior rather than a persistent direct drug effect. The authors recommend collecting samples before and after preparatory sessions and treatment to help separate these possibilities.

This creates another important distinction: even if a psychedelic improves a psychiatric symptom, researchers must still demonstrate whether immune changes caused that improvement, accompanied it, or were unrelated.

What Cannabis Research Adds to the Conversation

MyCannabis has explored the connections between cannabis, immunity, and the gut, including work on experimental CBD-derived compounds. Such research provides context for studying effects beyond the brain, but findings about modified molecules cannot automatically be applied to retail CBD oil.

A separate 2026 review of cannabinoid use and inflammatory biomarkers reinforces the need for caution. It included 46 studies involving 54,382 participants and found that observational cannabis use was associated with both pro-inflammatory and anti-inflammatory markers. Prospective studies did not show consistent effects.

These associations do not establish that cannabis caused the changes. They do, however, challenge the idea that its immune effects can be summarized by one universal label.

Meanwhile, a July 2026 laboratory study of THC, CBD, and immune cells reported reductions in particular inflammatory responses involving monocytes and astrocytes. That offers a specific mechanistic lead, rather than proof that cannabis treats inflammatory brain disease.

The lesson across these fields is precision. A particular molecule, at a particular dose, in a particular biological setting may produce a useful effect. That is a narrower and more informative claim than saying an entire substance category reduces inflammation.

Does the Research Support Microdosing or Combining Cannabis?

The review discusses preclinical findings suggesting that relatively low doses may sometimes produce stronger anti-inflammatory effects. This does not establish an effective human microdosing regimen. Animal dosing, compound potency, and tissue exposure cannot be translated directly into consumer recommendations.

The review also provides no clinical evidence that combining cannabis with psychedelics improves inflammatory outcomes. Shared interest in immune signaling is not evidence of a beneficial combination.

Readers considering CBD separately can consult the CBD buying guide for Canada for product-selection context. Product quality and lawful access are separate questions from whether a product effectively treats a diagnosed condition. This psychedelic review cannot answer the latter for CBD.

What Better Psychedelic Trials Need to Demonstrate

The review identifies substantial differences in compounds, doses, tissues, biomarkers, and study designs. It also notes small-study effects in the animal literature, which could reflect publication bias or methodological differences. Positive experiments may therefore present a more encouraging picture than the complete evidence would support.

The FDA’s current psychedelic drug development resources reflect growing regulatory attention to this field. Interest in development, however, does not resolve the specific question of anti-inflammatory efficacy.

The next convincing studies should:

• Measure baseline inflammation and recruit clearly defined patient groups.
• Use appropriate controls and repeated measurements to separate drug effects from other influences.
• Connect immune changes with meaningful clinical benefits and assess safety over time.

The most promising outcome may be a targeted therapy for a defined group rather than a general anti-inflammatory product. Whether that approach succeeds remains an open question. For now, the review offers credible reasons to investigate psychedelic immune effects, while preserving the distinction between a research opportunity and a treatment ready for patients.

References:

¹ Lerche, A. S., Kelley, D. P., Benros, M. E., Billac, G., Bradley, E. R., Heifets, B., Woolley, J., Nishimi, K., & O’Donovan, A. (2027). Are psychedelics anti-inflammatory? A systematic review and meta-analysis of studies examining the immunomodulatory effects of serotonergic psychedelics. Brain, Behavior, and Immunity, 139, Article 107033. https://doi.org/10.1016/j.bbi.2026.107033